The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multimodality evaluation of excision repair cross-complementation 1 (ERCC1) expression as a predictive biomarker for platinum resistance in epithelial ovarian cancer (EOC).
C. O. Michie
No relevant relationships to disclose
L. Song
No relevant relationships to disclose
D. Faratian
No relevant relationships to disclose
J. Orr
No relevant relationships to disclose
T. Rye
No relevant relationships to disclose
J. Clark
Employment or Leadership Position - MDxHealth
J. M. Bartlett
No relevant relationships to disclose
D. J. Harrison
Consultant or Advisory Role - Response Genetics (U)
Research Funding - Response Genetics
D. Melton
No relevant relationships to disclose
A. Williams
No relevant relationships to disclose
C. Gourley
No relevant relationships to disclose